GSK

73% of patients do not feel empowered to overcome their gynaecologic cancer diagnosis, according to the Your Cancer Is Our Challenge survey. Gynaecologic cancer can impact every aspect of a patient’s life, from their wellbeing to body image to maintaining activities and sexual health. Yet societal taboos can make it difficult for patients to speak openly about these concerns or seek the support they need, leaving them feeling less informed. Explore our patient resources here: https://gsk.to/4rdXMOF #WorldGODay2026

Back from #WCLC26, having spent the past few days in Seoul with our GSK teams across multiple external engagements and scientific sessions. Across all these engagements, one theme kept coming through clearly: lung cancer remains the leading cause of cancer death globally. For me, that statistic is never just a number, behind it are patients with NSCLC and SCLC facing low survival rates, high recurrence, treatment resistance and a real toll on quality of life. It's one of the greatest areas of unmet need in oncology, and one of our biggest priorities at GSK. That priority is built on deep biological insights matched with the right therapeutic approach, developed on validated targets and modalities where the depth of our expertise keeps growing. As our understanding of lung cancer biology advances, so does our ability to match the right therapeutic modality to the right target, tumor type and patient, pursuing deep and durable responses, overcoming resistance, and reducing the burden treatment places on patients' lives. This work is personal for me. Like so many families, I have also been impacted recently by the loss of a family member to cancer, and watching what the disease takes stays with me through every conversation I've had since. It's part of why this research matters so much, beyond the data and the science. The conversations I had in Seoul reinforced why a diverse, differentiated portfolio matters for meeting patients' evolving needs everywhere. Proud of the team driving this work, and optimistic about what's ahead. Ali Çimen Ahmed Rabie Eric Richards Zeshaan Rasheed Klaas Bakker Andrea Chassot (Agostinho), MD Christina Schiff Dolim L. Yeganeh A. Hildur Helgadottir Yufan (Frank) Liu, PharmD Anthony Vaganos Steve Pessagno

We’re committed to advancing new research and precision-based treatment options for people with lung cancer. As we wrap up #WCLC26 in Seoul, we’re feeling energised after seeing the global lung cancer community come together to share the latest research and advance conversations on improving outcomes for people with lung cancer. Innovations in molecular profiling, targeted therapies, and antibody-drug conjugates are redefining treatment approaches. Here at GSK, we’re focused on applying these innovations to our growing lung cancer portfolio where we are working to ensure the right therapeutic modality is matched to the right target, tumour type and patient need. Check out some of our team onsite 👇

#News for #investors and #media: We have entered a licence agreement with Chimagen Biosciences for an investigational T-cell engager for multiple myeloma, advancing our leadership ambitions in blood cancer. Find out more: https://gsk.to/4xXDCLB

#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer. Learn more: https://gsk.to/3SFIaa8

#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline. Learn more: https://gsk.to/4yFCHiR

Even though lung cancer is the most commonly diagnosed cancer worldwide, treatment is not “one-size-fits-all.” That’s because lung cancer is not one disease; it has many distinct subtypes, with many different treatment approaches, often tailored to the individual disease and patient. Swipe through for some fast facts about lung cancer and why continued research and innovation matters 👉 At GSK, we're committed to advancing innovative research and precision-based treatment options for people living with lung cancer. #WCLC2026

More than 400 million people are living with chronic obstructive pulmonary disease (COPD) and it is the third leading cause of death globally. Our work is looking beyond the lung, to the impact of the disease on wider organ systems that are under strain from the inefficiency of the lung. Through data shared at #ERSCongress and our accelerated pipeline we’re looking to target the drivers of the disease to keep patients out of hospital and transform patient outcomes. Learn more about COPD https://gsk.to/4AchVJh

100+ miles across Iceland. 🚴One compelling global cause. Join us in celebrating our two GSK cyclists, Patrick and Omar, who joined the International Myeloma Foundation in the third annual Iceland Cycling Expedition.🚴 The riders pedalled across volcanic terrain to raise awareness about the unmet needs of people living with multiple myeloma. A huge shoutout to our colleagues who took on this incredible journey. 👏 Learn more about our support for people living with multiple myeloma: https://gsk.to/4gY50lj #BloodCancerAwarenessMonth